by Brandon Li
Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation. Looking for a clinical trial? Visit us at www.withpower.com
Language
🇺🇲
Publishing Since
9/27/2023
See how your podcast performs across key metrics
Recommendations available
Unlock the full report to see detailed tips
Recommendations available
Unlock the full report to see detailed tips
Unlock comprehensive insights including:
See how your show performs across every key metric
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
July 23, 2026
Most people still think gout is a lifestyle condition caused primarily by diet. But this belief is a big reason patients have been underserved for decades. In this episode of Power to the Patients, Brandon Li sits down with James Mackay, CEO and co-founder of Crystalys Therapeutics, to explore what gout patients really need. They unpack what went wrong with Zurampic, why Dotinurad’s profile gives Crystalys Therapeutics a reason to come back to gout and how better trial design could finally move the field beyond old assumptions. For decades, gout has often been framed as a disease caused by lifestyle choices. This episode reframes the conversation entirely.
July 7, 2026
Learn about clinical trial design for small molecule therapies using biomarkers in Alzheimer's research and AI in drug development. Brandon Li talks with Sacha Schermerhorn, Founder and CEO of Babylon Biosciences. They discuss why the industry needs to rethink disease pathology, how to recruit elite talent out of retirement, and the role of fine-tuned AI models in predicting clinical outcomes for patients.
May 13, 2026
Dr. Aaron Koenig, Chief Medical Officer at Delix Therapeutics, sheds light on a new class of medicines designed to promote neuroplasticity without the hallucinogenic effects associated with psychedelics. On this episode of Power to the Patients, Koenig explains to host Brandon Li how neuroplasticogens could provide scalable treatments for depression and other serious brain disorders, why separating plasticity from psychedelic experiences matters for clinical development, and how emerging biomarkers such as qEEG may help measure brain changes in patients. The conversation spans scientific rationale, clinical challenges, and long term potential of plasticity-based therapeutics in psychiatry and neurology.
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Gerard Sanacora
Guest
Dina Burkitbayeva
Guest
Joel Raskin
Guest
Katie Baca-Motes
Guest
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
Power to the Patients is a LinkedIn Live and podcast series hosted by Power where clinical research leaders across sponsors, sites, CROs, and patient advocacy groups discuss patient centricity in clinical trials. We explore the bottlenecks in today's systems, challenge the status quo and talk about future opportunities for innovation.
Looking for a clinical trial? Visit us at www.withpower.com
This podcast updates daily.
This podcast is available on 7 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Yes, this podcast regularly features guests.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.